Table 2.
Association between Efavirenz Metabolism Genotypes* and Treatment Endpoints
| Endpoint (# observations) | Unadjusted OR (95% CI) |
p value |
† Adjusted OR (95% CI) |
p value |
|---|---|---|---|---|
| Composite Failure (n=801) |
1·13 (0·92, 1·39) | 0·23 | 1·13 (0.92, 1.39) | 0·25 |
| Virologic Failure (n=615) |
1·21 (0·88, 1·67) | 0·25 | 1·24 (0·89, 1·73) | 0·20 |
| Loss to Follow-Up (n=767) |
1·02 (0·79, 1·31) | >0·5 | 1·01 (0·79, 1·31) | >0·5 |
| Death (n=801) |
1·35 (0·83, 2·20) | 0·23 | 1·35 (0·83, 2·20) | 0·22 |
*
Metabolism included as ordinal variable at three levels: extensive (base case), intermediate and slow.
†
Adjusted for log10 baseline HIV RNA